Discussing the Option of Canakinumab in NSCLC

Edward B. Garon, MD, MS, professor of medicine, Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the mechanism of action of canakinumab (Ilaris).

Canakinumab is an interleukin-1beta inhibitor (IL-1β) being evaluated as a potential treatment option for patients with non–small cell lung cancer (NSCLC).

Within the phase 3 CANOPY-A study (NCT03447769), adjuvant canakinumab is being explored in patients with completely resected NSCLC. However, the agent failed to meet its primary end point of disease-free survival, according to data presented at the 2022 ESMO.

Transcription:

0:08 | Canakinumab is a high-affinity monoclonal antibody directed against an interleukin-1beta. IL-1β has been considered a key mediator of inflammation. One of the unique aspects of canakinumab is that it is an approved drug in many countries, including the United States, for a variety of inflammatory disorders.

0:28 | There has been a tremendous amount of preclinical data looking at IL-1β and other mediators of inflammation in lung cancer. Prior to the development of canakinumab, there was much less clinical data available looking at this pathway.